Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MSON's Cash to Debt is ranked higher than
90% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. MSON: No Debt )
MSON' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: No Debt

Equity to Asset 0.89
MSON's Equity to Asset is ranked higher than
94% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MSON: 0.89 )
MSON' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.89
Current: 0.89

0.5
0.89
Interest Coverage No Debt
MSON's Interest Coverage is ranked higher than
71% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. MSON: No Debt )
MSON' s 10-Year Interest Coverage Range
Min: 2.41   Max: 9999.99
Current: No Debt

2.41
9999.99
F-Score: 7
Z-Score: 26.28
M-Score: -3.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -6.34
MSON's Operating margin (%) is ranked higher than
61% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 6.13 vs. MSON: -6.34 )
MSON' s 10-Year Operating margin (%) Range
Min: -35.87   Max: 23.51
Current: -6.34

-35.87
23.51
Net-margin (%) 15.51
MSON's Net-margin (%) is ranked higher than
92% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. MSON: 15.51 )
MSON' s 10-Year Net-margin (%) Range
Min: -28.56   Max: 19.78
Current: 15.51

-28.56
19.78
ROE (%) 19.37
MSON's ROE (%) is ranked higher than
93% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. MSON: 19.37 )
MSON' s 10-Year ROE (%) Range
Min: -21.42   Max: 31.93
Current: 19.37

-21.42
31.93
ROA (%) 16.63
MSON's ROA (%) is ranked higher than
97% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. MSON: 16.63 )
MSON' s 10-Year ROA (%) Range
Min: -18.21   Max: 24.04
Current: 16.63

-18.21
24.04
ROC (Joel Greenblatt) (%) -18.82
MSON's ROC (Joel Greenblatt) (%) is ranked higher than
63% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. MSON: -18.82 )
MSON' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -91.78   Max: 50.2
Current: -18.82

-91.78
50.2
Revenue Growth (3Y)(%) 8.80
MSON's Revenue Growth (3Y)(%) is ranked higher than
82% of the 346 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. MSON: 8.80 )
MSON' s 10-Year Revenue Growth (3Y)(%) Range
Min: -35.2   Max: 36.3
Current: 8.8

-35.2
36.3
» MSON's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MSON Guru Trades in Q1 2014

Jim Simons 114,400 sh (-2.89%)
» More
Q2 2014

MSON Guru Trades in Q2 2014

Jim Simons 116,100 sh (+1.49%)
» More
Q3 2014

MSON Guru Trades in Q3 2014

Jim Simons 120,300 sh (+3.62%)
» More
Q4 2014

MSON Guru Trades in Q4 2014

Jim Simons 138,100 sh (+14.80%)
» More
» Details

Insider Trades

Latest Guru Trades with MSON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.70
MSON's P/E(ttm) is ranked higher than
83% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 201.60 vs. MSON: 33.70 )
MSON' s 10-Year P/E(ttm) Range
Min: 5.18   Max: 303
Current: 33.7

5.18
303
PE(NRI) 35.50
MSON's PE(NRI) is ranked higher than
84% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 140.40 vs. MSON: 35.50 )
MSON' s 10-Year PE(NRI) Range
Min: 19.77   Max: 200
Current: 35.5

19.77
200
P/B 5.20
MSON's P/B is ranked higher than
61% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. MSON: 5.20 )
MSON' s 10-Year P/B Range
Min: 0.26   Max: 5.83
Current: 5.2

0.26
5.83
P/S 5.00
MSON's P/S is ranked higher than
60% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.68 vs. MSON: 5.00 )
MSON' s 10-Year P/S Range
Min: 0.12   Max: 5.71
Current: 5

0.12
5.71
PFCF 41.10
MSON's PFCF is ranked higher than
85% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MSON: 41.10 )
MSON' s 10-Year PFCF Range
Min: 16.81   Max: 462
Current: 41.1

16.81
462
POCF 38.88
MSON's POCF is ranked higher than
78% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 78.33 vs. MSON: 38.88 )
MSON' s 10-Year POCF Range
Min: 11.09   Max: 278
Current: 38.88

11.09
278
EV-to-EBIT -68.32
MSON's EV-to-EBIT is ranked higher than
62% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 73.27 vs. MSON: -68.32 )
MSON' s 10-Year EV-to-EBIT Range
Min: -82.3   Max: 116.6
Current: -68.32

-82.3
116.6
Current Ratio 7.20
MSON's Current Ratio is ranked higher than
92% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. MSON: 7.20 )
MSON' s 10-Year Current Ratio Range
Min: 1.55   Max: 9.22
Current: 7.2

1.55
9.22
Quick Ratio 5.32
MSON's Quick Ratio is ranked higher than
90% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. MSON: 5.32 )
MSON' s 10-Year Quick Ratio Range
Min: 0.76   Max: 7.5
Current: 5.32

0.76
7.5
Days Inventory 229.40
MSON's Days Inventory is ranked higher than
63% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 166.67 vs. MSON: 229.40 )
MSON' s 10-Year Days Inventory Range
Min: 81.28   Max: 397.65
Current: 229.4

81.28
397.65
Days Sales Outstanding 65.23
MSON's Days Sales Outstanding is ranked higher than
79% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.87 vs. MSON: 65.23 )
MSON' s 10-Year Days Sales Outstanding Range
Min: 55.99   Max: 111.68
Current: 65.23

55.99
111.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.70
MSON's Price/Net Cash is ranked higher than
88% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MSON: 16.70 )
MSON' s 10-Year Price/Net Cash Range
Min: 1.88   Max: 86.82
Current: 16.7

1.88
86.82
Price/Net Current Asset Value 9.30
MSON's Price/Net Current Asset Value is ranked higher than
87% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 327.00 vs. MSON: 9.30 )
MSON' s 10-Year Price/Net Current Asset Value Range
Min: 0.72   Max: 8.6
Current: 9.3

0.72
8.6
Price/Tangible Book 6.40
MSON's Price/Tangible Book is ranked higher than
69% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. MSON: 6.40 )
MSON' s 10-Year Price/Tangible Book Range
Min: 0.43   Max: 8.04
Current: 6.4

0.43
8.04
Price/DCF (Projected) 145.00
MSON's Price/DCF (Projected) is ranked higher than
77% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MSON: 145.00 )
MSON' s 10-Year Price/DCF (Projected) Range
Min: 0.66   Max: 137.44
Current: 145

0.66
137.44
Price/Median PS Value 4.90
MSON's Price/Median PS Value is ranked higher than
52% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. MSON: 4.90 )
MSON' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 4.93
Current: 4.9

0.13
4.93
Price/Graham Number 3.20
MSON's Price/Graham Number is ranked higher than
84% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MSON: 3.20 )
MSON' s 10-Year Price/Graham Number Range
Min: 0.47   Max: 8.33
Current: 3.2

0.47
8.33
Earnings Yield (Greenblatt) -1.70
MSON's Earnings Yield (Greenblatt) is ranked higher than
63% of the 468 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. MSON: -1.70 )
MSON' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.6   Max: 5.9
Current: -1.7

-1.6
5.9

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:MX9.Germany,
Misonix Inc a New York corporation organized in 1959. The Company designs, manufactures, markets and develops minimally invasive ultrasonic medical device products. These products include the BoneScalpel cutting system which is used among other things for surgical procedures of the spine and on Maxillofacial procedures, the SonaStar Surgical Aspirator which is used to emulsify and remove soft and hard tumors, the SonicOne Wound Cleansing and Debridement System which offers tissue specific debridement and cleansing of wounds for effective removal of devitalized tissue and fibrin deposits while sparing viable cells and the AutoSonix ultrasound cutting and coagulating system which is distributed and marketed for Misonix through Mentor Corporation, a subsidiary of Johnson & Johnson. The Company applications include the ability to transect or shape bone, ablate and aspirate both soft and hard tissue, cleanse and debride advanced wounds and remove unwanted body fat. Among clinical specialties served are: Spine Surgery, Skull-Based Surgery (i.e., Cranio-Maxillo-Facial, Neurosurgery, Orthopedic Surgery and Plastic surgery). The Company sells its SonicOne Wound Cleansing and Debridement System, through direct sales persons and sales agents or distributors worldwide. The Companys main competitors are Johnson & Johnson, Valley Lab, a division of Tyco Healthcare, Integra Life Sciences, Inc., Sööring, and Stryker. The Companys medical device products are subject to the regulatory requirements of the U.S. Food and Drug Administration.
» More Articles for MSON

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight May 19 2013 
comment on MSON Mar 06 2013 
MISONIX Inc. (MSON) CEO Michael A Jr Mcmanus buys 5,000 Shares Dec 02 2009 
MISONIX Inc. Reports Operating Results (10-Q) Nov 16 2009 
MISONIX Inc. Reports Operating Results (10-K) Sep 28 2009 
FirstEnergy Files Application To Consolidate Transmission Assets Into PJM Aug 17 2009 
Misonix Announces the Sale of Its Labcaire Business for up to $5.6 Million Aug 05 2009 
MISONIX Inc. Reports Operating Results (10-Q) May 12 2009 
Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008 Feb 09 2009 
Misonix Announces New HIFU Distribution Agreement for Italy Jan 05 2009 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Apr 01 2015
Misonix Announces Presentation At Leading Wound Conference Confirms SonicOne O.R. More Effective at... Mar 17 2015
Misonix Announces Presentation At Leading Wound Conference Confirms SonicOne O.R. More Effective at... Mar 17 2015
Michael A. McManus, Jr., CEO of Misonix, Selected As A Top Micro-Cap CEO By ExecRank Feb 20 2015
Michael A. McManus, Jr., CEO of Misonix, Selected As A Top Micro-Cap CEO By ExecRank Feb 20 2015
MISONIX INC Financials Feb 11 2015
10-Q for Misonix, Inc. Feb 06 2015
MISONIX INC Files SEC form 8-K, Results of Operations and Financial Condition, Submission of Matters... Feb 05 2015
Misonix Inc Earnings Call scheduled for 4:30 pm ET today Feb 04 2015
MISONIX INC Files SEC form 10-Q, Quarterly Report Feb 04 2015
Misonix, Inc. Announces Second Quarter Fiscal Year 2015 Financial Results Feb 04 2015
Q2 2015 Misonix Earnings Release - Before Market Open Feb 04 2015
Misonix Acquires Remaining Exclusive BoneScalpel™ Business from Aesculap Feb 03 2015
Misonix, Inc. To Report Second Quarter Fiscal Year 2015 Financial Results On Wednesday, February 4,... Jan 27 2015
After The Major Gains In Misonix, Who's Benefiting The Most? Dec 29 2014
Novel BoneScalpel Technique Published in Operative Neurosurgery Dec 02 2014
Novel BoneScalpel Technique Published in Operative Neurosurgery Dec 02 2014
SonicOne® Study Shows Improved Wound Healing In Patients with Peripheral Vascular Disease Nov 20 2014
SonicOne® Study Shows Improved Wound Healing In Patients with Peripheral Vascular Disease Nov 20 2014
Misonix Trains Surgeons on the BoneScalpel™ at the 2014 North American Spine Society Annual... Nov 19 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK